Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05300555
Other study ID # SDC 5074//20/103
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 5, 2021
Est. completion date November 1, 2022

Study information

Verified date March 2022
Source University of Sao Paulo General Hospital
Contact Eduardo Lima, Doctor
Phone +55 11 26615352
Email eduglima@yahoo.com.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Coronary artery bypass graft (CABG) surgery is a common intervention in patients with coronary artery disease (CAD). The presence of new postoperative atrial fibrillation / atrial flutter (POAF) occurs in 15-40% of patients undergoing this procedure, with a high rate of complications, including increased hospital length of stay, with a consequent increase in the costs. In addition, the presence of POAF increases the rate of thromboembolic events such as stroke and mortality in the short and long term. Anticoagulant treatment in patients with atrial fibrillation and atrial flutter (AF) lato sensu is already a well-established therapy in patients at high risk, defined by CHADS-VASC greater than or equal to 2. The use of direct-acting anticoagulants (DOACS) is standard therapy for those patients. In the POAF scenario, there is a recommendation for anticoagulation in high-risk patients for at least 30 days, however, despite being an entity with a poor prognosis in the short and long term, it is an undertreated entity. At present, there is no evidence of anticoagulant treatment of POAF with DOACS, and warfarin is the standard therapy. Warfarin is a drug that needs laboratory control of prothrombin time (PT) and anticoagulation bridge with other anticoagulants, usually using heparin and enoxaparin. We believe that because warfarin is the standard drug in this scenario, it is not prescribed on a regular basis, since it increases costs, length of hospital stay and is less effective than DOACS in AF lato sensu. Thus, the research project intends to compare the cost-effectiveness, assessed by QALY, related to the warfarin prescription strategy associated with bridge anticoagulation versus the rivaroxaban prescription in patients who presented POAF with a minimum duration of 12 hours or AF that requires intervention. Medications will be started during hospitalization. After randomization, anticoagulant medication will be started within 24 hours. The patient will be reassessed in 30 days and if there is no evidence of maintenance of AF, the anticoagulant medication will be discontinued and the standard treatment for CAD will be maintained. Secondary outcomes will be: clinical outcomes, such as: (1) Death; (2) stroke; (3) myocardial infarction (MI); (4) Readmission; (5) Systemic embolization; (6); Surgical reintervention; (6) Bleeding using the ISTH score; (7) Infection. The safety outcome will be the bleeding assessment according to the bleeding score of the ISTH (International Society on Thrombosis and Haemostasis). Considering that POAF is a prevalent entity and associated with a worse prognosis in the short and long term, as well as despite recommendations for guidelines to keep these patients anticoagulated, it is noted that the prescription of anticoagulation at hospital discharge is low. Considering that there is no clear evidence in studies on the use of DOAC in this population, we understand that the search for medications that lead to better cost-benefit, as well as better dosage and bleeding rates not lower than the use of warfarin, could lead to a higher rate prescribing anticoagulants for these patients, reducing costs, clinical and mortality outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date November 1, 2022
Est. primary completion date January 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - New atrial/flutter fibrillation / flutter lasting more than 12 hours in the postoperative period of CABG - Individuals in both sex over the age of 18 years Exclusion Criteria: - Inability to sign the free and informed consent form - Contraindication to anticoagulant therapy - Renal dysfunction with eGFR less than 30ml / min / 1.73m² or dialysis therapy - Patients with previous AF - Pregnancy - Concomitant valve surgery

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rivaroxaban 20 MG Oral Tablet
After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
Warfarin
After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued

Locations

Country Name City State
Brazil Heart Institute - University of São Paulo São paulo Sao Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo General Hospital

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cost-effectiveness between rivaroxaban and warfarin group The primary outcome will be the cost-effectiveness, assessed by QALY, of the treatments in both therapeutic groups (rivaroxaban and warfarin) during the hospital stay with follow-up for 30 days after hospital discharge. 30 days after hospital discharge
Secondary Bleeding according to ISTH bleeding score Security outcome 30 days after hospital discharge
Secondary Secondary outcome (1) Death; (2) stroke; (3) MI; (4) Readmission; (5) Systemic embolization; (6); Surgical reintervention; (6) Bleeding using the ISTH score; (7) Infection; 30 days after hospital discharge
See also
  Status Clinical Trial Phase
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Recruiting NCT04870424 - Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Phase 3
Completed NCT05818592 - Screening for Atrial Fibrillation With Self Pulse Monitoring N/A
Active, not recruiting NCT05780320 - A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery
Active, not recruiting NCT03866148 - Obstructive Sleep Apnoea and Cardiac Arrhythmias N/A
Withdrawn NCT05656170 - Stellate Ganglion to Prevent Atrial Fibrillation N/A
Active, not recruiting NCT05255224 - PARADISE: Predicting AF After Cardiac Surgery
Recruiting NCT04528511 - BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
Recruiting NCT04857268 - Diagnostic Validation of Wearable ECG Monitoring Patch, ATP-C120 N/A
Completed NCT04118270 - Shared Decision-Making: AFib 2gether Mobile App N/A
Active, not recruiting NCT03345615 - Standard Versus Intensive Monitoring After Myocardial Infarction Looking for Atrial Fibrillation N/A
Not yet recruiting NCT05841056 - Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial Phase 3
Recruiting NCT06275503 - STROKESTOP III - Optimized Method for Atrial Fibrillation Screening N/A
Recruiting NCT05149820 - Point of Care RandOmisation Systems for Performing Embedded Comparative Effectiveness Trials Of Routine Treatments Phase 4
Completed NCT03221777 - Atrial Fibrillation Occurring Transiently With Stress (AFOTS)
Not yet recruiting NCT03991754 - Prevention of New Onset AF After TAVI (PAF-TAVI Trial) Phase 3
Completed NCT03118518 - STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation N/A
Completed NCT03552588 - High Sensitivity Estimate of the Incidence of Atrial Fibrillation Occurring Transiently With Stress (AFOTS Incidence Study)
Recruiting NCT05444335 - Screening for Atrial Fibrillation in Elderly Women Older Than 70 Years N/A
Not yet recruiting NCT06458829 - Promoting Atrial Fibrillation Screening in Primary Care N/A